Cue Health (NYSEAMERICAN:HLTH) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Cue Health (NYSEAMERICAN:HLTHGet Rating) (TSE:NHC) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Cue Health Inc. is a health technology company. It offers individuals, enterprises, government agencies and healthcare provides access to lab-quality diagnostic testing at home, at work or at the point-of-care, all in a device. Cue Health Inc. is headquartered in San Diego. “

HLTH has been the subject of a number of other reports. Cowen decreased their target price on Cue Health from $15.00 to $10.00 in a research report on Wednesday, March 30th. Morgan Stanley decreased their target price on Cue Health from $12.00 to $11.00 and set an equal weight rating for the company in a research report on Wednesday, March 30th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $14.20.

HLTH opened at $6.56 on Tuesday. Cue Health has a 52-week low of $5.48 and a 52-week high of $22.55.

Cue Health (NYSEAMERICAN:HLTHGet Rating) (TSE:NHC) last posted its quarterly earnings data on Tuesday, March 29th. The healthcare company reported $0.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.11. The business had revenue of $192.51 million for the quarter. Sell-side analysts anticipate that Cue Health will post 1.32 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bleichroeder LP purchased a new position in Cue Health during the 3rd quarter worth $11,810,000. Harbor Investment Advisory LLC purchased a new position in Cue Health during the 4th quarter worth $134,000. Allworth Financial LP purchased a new position in Cue Health during the 4th quarter worth $469,000. BlackRock Inc. purchased a new position in Cue Health during the 3rd quarter worth $83,000. Finally, Point72 Hong Kong Ltd purchased a new position in Cue Health during the 3rd quarter worth $153,000.

Cue Health Company Profile (Get Rating)

Cue Health Inc, a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors.

Featured Stories

Get a free copy of the Zacks research report on Cue Health (HLTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cue Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Health and related companies with MarketBeat.com's FREE daily email newsletter.